Neuros Medical Secures $56M Series D Financing to Advance Commercialization of Altius®, the Only FDA-Approved Non-Opioid Therapy for Chronic Post-Amputation Pain

Jul 09, 2025 22:15 CST Updated 22:15

Neuros Medical

Neuros MedicalXuanCloth completedA new round of $56 million in oversubscribed financing, originally led by EQT Life Sciences,US Venture Partners, Amzak Health, Osage University Partners, Sectoral Asset Management, Aperture Venture Partners, and others participated as co-investors. The proceeds from this financing round will be primarily used to advance its core product.AltiusCommercialization Process and Subsequent Development in the United States.

Investor Evaluation

“Neuros Medical is dedicated to addressing the most urgent yet long-overlooked challenges in the field of chronic pain management. We believe that Altius has the potential to significantly improve the quality of life for amputees, and we are honored to collaborate with this team to bring this therapy to market.”

---Fouad Azzam EQT Life SciencesPartner

Executive Evaluation

“We thank our new and existing investors for supporting our mission to ‘Alleviate Pain, Restore Life’ and helping millions of patients suffering from chronic post-amputation pain. This financing round underscores the urgent unmet medical needs of the amputee community, enabling us to scale our commercial operations to promote this breakthrough technology, while providing healthcare professionals with much-needed non-opioid solutions and support to help deliver care at the highest standards.”

---David Veino President and Chief Executive Officer of Neuros Medical

Post-amputation pain is a severely undertreated area, affecting up to 80% of amputees nationwide in the United States, with a current lack of effective non-opioid treatment options.AltiusPrecision Neuromodulation via a Patient-Controlled, On-Demand Therapy Model: The Only FDA-Approved Solution for Post-Amputation Pain

Altius

Altiusis a treatment for phantom limb pain following chronic amputationPainand neurostimulation products for residual limb pain.AltiusUseNeuros Medicalpatent---"On-Demand Bioelectronic Nerve Block"technology to target the source of pain, namely the affected peripheralNerve.

AltiusIt consists of an implantable pulse generator with an integrated rechargeable battery, cuff electrodes, and external devices (clinician programmer, patient controller, and charger).

AltiusCapable of addressing pain at its source,

The pulse generator is implanted into the patient's body through surgery.Cuff electrodes are implanted onto the nerves at the amputation site (peripheral nerves);

Provides unique bioelectric nerve block

Transmit high-frequency bioelectrical signals to the target sensory nerve to block pain signals;

Patient Control

Patients use the controller to initiate a 30-minute treatment, allowing them to use it freely as needed.

Neuros Medical

Neuros Medicalis an innovative neuromodulation company, whose developedAltiusNeurostimulators can be used to treat chronic post-amputation pain (phantom limb pain and residual limb pain).